Published in Women's Health Weekly, December 15th, 2005
"The goal is to identify genetic factors that will enable physicians to predict the outcome and efficacy of carboplatin/tamoxifen treatment, a standard therapy for victims of breast cancer," stated Hector J. Gomez, MD, PhD, chairman and chief medical officer of DNAPrint genomics.
"Combining Genomics Collaborative's extensive network of physician-managed centers with DNAPrint's proprietary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly